CN102327451A - Chinese medicinal composition for treating chronic sinusitis - Google Patents
Chinese medicinal composition for treating chronic sinusitis Download PDFInfo
- Publication number
- CN102327451A CN102327451A CN201110309935A CN201110309935A CN102327451A CN 102327451 A CN102327451 A CN 102327451A CN 201110309935 A CN201110309935 A CN 201110309935A CN 201110309935 A CN201110309935 A CN 201110309935A CN 102327451 A CN102327451 A CN 102327451A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicaments
- radix
- medicinal composition
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and discloses a Chinese medicinal composition for treating chronic sinusitis. The Chinese medicinal composition is prepared from the following raw material medicaments in part by weight: 25 to 35 parts of honeysuckle flower, 15 to 25 parts of biond magnolia flower, 10 to 20 parts of siberian cocklour fruit, 10 to 20 parts of angelica dahurica, 7 to 17 parts of baical skullcap root, 10 to 20 parts of Chinese thorowax root, 10 to 20 parts of gentian, 7 to 17 parts of rhizoma anemarrhenae, 15 to 25 parts of astragalus, 5 to 15 parts of manchurian wildginger and 5 to 15 parts of liquoric root. The Chinese medicinal composition has the advantages that: chief medicaments, deputy medicaments, adjuvant medicaments and envoy medicaments have appropriate compatibility; the selected medicaments are excellent and combined; the Chinese medicinal composition has the effects of clearing heat and drying damp, diffusing and freeing the orifices, tonifying vitality and strengthening exterior, and strengthening body resistance and eliminating evil, can quickly remove sinus inflammation, restrain mucosal secretion and quickly eliminate clinical symptoms, has the effects of reconstructing damaged nasal mucosa and recovering the cleaning function of nasal mucosa cilia, consolidates the curative effect, does not have adverse effects after being taken for a long time, is safe to take, has an exact curative effect and is worth of clinical popularization.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition of treating chronic sinusitis.
Background technology
Chronic sinusitis is common clinical, frequently-occurring disease, most because of the acute sinusitis treatment untimely or thoroughly due to.Because serious environmental is polluted day by day, people's morbidity in the whole world about 15%.Preschool back school age, the section child-the teenager sickness rate was higher, and ascendant trend is year by year arranged.It mainly shows as the glutinous pus tears of stream, nasal obstruction, with dizzy, feeling of fullness in the head even hypomnesis.Open radical correction of traditional nasal sinuses and the nasal endoscope operation of promoting in recent years can yet be regarded as and treated the effective ways of chronic sinusitis.Yet; Seeing that child-teenager nasal sinuses structural development is incomplete as yet; The sinunasal physiological function obstacle reversibility that inflammation causes is big, and child-teenager is difficult to tolerate invasive surgery, and most doctors are devoted to seek child-teenager chronic sinusitis expectant treatment method.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition of treating chronic sinusitis.
For realizing above-mentioned purpose, the technical scheme that the present invention takes is following:
A kind of Chinese medicine composition of treating chronic sinusitis is processed by each crude drug of following portions by weight: 25 ~ 35 parts of Flos Loniceraes, 15 ~ 25 parts of Flos Magnoliaes, 10 ~ 20 parts of Fructus Xanthii, 10 ~ 20 parts of the Radixs Angelicae Dahuricae, 7 ~ 17 parts of Radix Scutellariaes, 10 ~ 20 parts of Radix Bupleuri, 10 ~ 20 parts of Radix Gentianaes, 7 ~ 17 parts of the Rhizoma Anemarrhenaes, 15 ~ 25 parts of the Radixs Astragali, 5 ~ 15 parts of Herba Asaris, 5 ~ 15 parts in Radix Glycyrrhizae.
Optimum formula of the present invention is (weight portion): 30 parts of Flos Loniceraes, 20 parts of Flos Magnoliaes, 15 parts of Fructus Xanthii, 15 parts of the Radixs Angelicae Dahuricae, 12 parts of Radix Scutellariaes, 15 parts of Radix Bupleuri, 15 parts of Radix Gentianaes, 12 parts of the Rhizoma Anemarrhenaes, 20 parts of the Radixs Astragali, 10 parts of Herba Asaris, 10 parts in Radix Glycyrrhizae.
Traditional Chinese medical science traditional theory thinks that chronic sinusitis belongs to " nasal sinusitis " category.It is because deficiency of the spleen and lung, instability of surface, and evil poison is damp and hot to gather that nasal sinuses, nose key are corrupt to suppurate and cause.The present invention uses Flos Lonicerae, Fructus Xanthii, Flos Magnoliae to be principal agent, and lung qi dispersing is sensible, the heat clearing and damp drying spleen invigorating.Radix Scutellariae, the Radix Astragali, Herba Asari, the Rhizoma Anemarrhenae are ministerial drug, wherein, and the Radix Astragali, benefiting QI for strengthening the superficies, strengthening vital QI to eliminate pathogenic factors; Radix Scutellariae, the removing summer-heat lung-heat; Herba Asari, analgesic, antiinflammatory, analgesia; The Rhizoma Anemarrhenae, clearing away heat-fire, nourshing Yin and drynsessmoistening prescription.Radix Bupleuri, Radix Gentianae, the Radix Angelicae Dahuricae are adjuvant drug, wherein, and Radix Bupleuri, dispelling wind and heat pathogens; Radix Gentianae, the fire of heat clearing and damp drying, eliminating pathogen in the liver gallbladder; The Radix Angelicae Dahuricae, cold expelling is sensible, wind-expelling pain-stopping, detumescence and apocenosis, the priming sick institute that goes directly.Radix Glycyrrhizae is a messenger drug, clearing away heat-fire, coordinating the actions of various ingredients in a prescription.Medicine monarch compatibility of the present invention is appropriate, selects YAOJING good, and all medicines share; Have heat clearing and damp drying, a surname and loose and sensiblely not only can eliminate the nasal sinuses inflammation fast, suppress mucosa and secrete with, benefiting QI for strengthening the superficies, the double effect of executing of strengthening vital QI to eliminate pathogenic factors; Eliminate clinical symptoms rapidly; And have the effect of repairing ruined nasal mucosa, recovery nasal mucosa cilium cleaning function, so curative effect is good, be worth clinical expansion.
Method for preparing: process any acceptable clinically preparation by conventional method, can choose and add corresponding conventional adjuvant according to the needs of different preparations.The preferred watered pill of preparation or granule, the more preferably watered pill.
The advantage of medicine of the present invention: the monarch compatibility is appropriate, selects YAOJING good, and all medicines share; Having heat clearing and damp drying, a surname looses sensible with, benefiting QI for strengthening the superficies, the double effect of executing of strengthening vital QI to eliminate pathogenic factors; Not only can eliminate the nasal sinuses inflammation fast, suppress the mucosa secretion, eliminate clinical symptoms rapidly; And have the effect of repairing ruined nasal mucosa, recovery nasal mucosa cilium cleaning function, so curative effect is good; Take for a long time and have no adverse reaction, safe in utilization, determined curative effect is worth clinical expansion.
The specific embodiment
Embodiment 1
By following weight, take by weighing each crude drug: Flos Lonicerae 30g, Flos Magnoliae 20g, Fructus Xanthii 15g, Radix Angelicae Dahuricae 15g, Radix Scutellariae 12g, Radix Bupleuri 15g, Radix Gentianae 15g, Rhizoma Anemarrhenae 12g, Radix Astragali 20g, Herba Asari 10g, Radix Glycyrrhizae 10g.After above each crude drug cleaned up, dries, pulverize and be fine flour, cross 200 mesh sieves, the general watered pill (being commonly called as the Flos Lonicerae ball), the every ball 0.1g of processing.
Embodiment 2
By following weight, take by weighing each crude drug: Flos Lonicerae 25g, Flos Magnoliae 15g, Fructus Xanthii 10g, Radix Angelicae Dahuricae 10g, Radix Scutellariae 7g, Radix Bupleuri 10g, Radix Gentianae 10g, Rhizoma Anemarrhenae 7g, Radix Astragali 15g, Herba Asari 5g, Radix Glycyrrhizae 5g.After above each crude drug cleaned up, dries, pulverize and be fine flour, cross 200 mesh sieves, the general watered pill (being commonly called as the Flos Lonicerae ball), the every ball 0.1g of processing.
Embodiment 3
By following weight, take by weighing each crude drug: Flos Lonicerae 35g, Flos Magnoliae 25g, Fructus Xanthii 20g, Radix Angelicae Dahuricae 20g, Radix Scutellariae 17g, Radix Bupleuri 20g, Radix Gentianae 20g, Rhizoma Anemarrhenae 17g, Radix Astragali 25g, Herba Asari 15g, Radix Glycyrrhizae 15g.After above each crude drug cleaned up, dries, pulverize and be fine flour, cross 200 mesh sieves, the general watered pill (being commonly called as the Flos Lonicerae ball), the every ball 0.1g of processing.
The observation on Clinical Application report
One, basic document (in January, 2002 ~ 2011 year JIUYUE)
Accept patient's 2000 examples altogether for medical treatment, male's 1203 examples wherein, women's 797 examples, the age is 3--60 year, the shortest person of the course of disease two months, elder 30 years is surplus.
Two, diagnostic criteria
(1), symptom
1, cardinal symptom: nasal obstruction, stickiness, purulence nasal mucus.
2, minor symptom: women's head-ornaments portion distending pain, hyposmia or forfeiture.
Be foundation with above-mentioned two or more relevant symptoms during diagnosis, the nasal obstruction in the cardinal symptom wherein, stickiness, the purulence nasal mucus must the tool one of which.
(2), inspection
1, nasal cavity inspection: derive from the glutinous purulent secretion of middle nasal meatus, olfactory cleft, middle nasal meatus's mucosa is congested, edema or nasal polyp is arranged.
2, imaging examination: CT scan shows hole mouth nasal meatus complex or nasal meatus mucosa pathological changes.
Three, criterion of therapeutical effect
Cure: clinical symptom disappearance, nasal cavity inspection and CT scan all show no pathological changes.
Produce effects: clinical symptoms is significantly improved, and nasal cavity inspection and the equal lesions showed of CT scan are significantly improved.
Invalid: clinical symptoms does not have obvious improvement, and nasal cavity inspection and the equal lesions showed of CT scan do not have obvious improvement.
Four, Therapeutic Method
The embodiment of the invention 1 Flos Lonicerae ball, each 9 gram (90)/children below 12 years old 6 grams (60) of being grown up, every day 2 times is oral, continues to take 2 weeks.
Five, therapeutic effect
Cure 969 examples, produce effects 931 examples, invalid 100 examples, total effective rate is 95%.
Model case
Case 1
The Wang, man, 11 years old; The village, temple, Si Zhuan township village school is learned the student, and on JIUYUE 25th, 2006 went to a doctor, and tells frons headache, feeling of fullness in the head, the dense thick tears of stream 2 years; Treatment effect is not good in many ways for warp, and the nasal sinuses CT examination shows: the bilateral frontal sinusitis is suppurated (fluid level is arranged), gives the embodiment of the invention 1 Flos Lonicerae ball 6 grams; Every day 2 times is oral, and headache after 7 days, feeling of fullness in the head disappear, dense thick tears reduce, the recovery from illness of 2 weeks.
Case 2
Ma, man, 13 years old, the northern junior middle school student of institute in the Nanyue County one; Went to a doctor on August 16th, 2007, tell frons, the headache of bilateral temple place, dizzy 5 months, the distractibility of listening to the teacher; Hypomnesis, school grade descends, and the nasal sinuses CT examination shows: bilateral sinus frontalis, maxillary sinusitis (fluid level is arranged); Give the embodiment of the invention 2 Flos Lonicerae balls 9 gram, every day 2 times is oral, 2 week the back transference cures.
Case 3
Korea Spro, woman, 56 years old, Korea Spro Zhang Zhennan street, Nanyue County village peasant; On July 20th, 2007 went to a doctor, and told headache, dizziness 30 years, took " tablet for alleviating pain " pain relieving every day, oneself suspected that brain is ill; Cranium brain MRI inspection is done in requirement, and check result shows: cranium brain no abnormality seen, and bilateral frontal sinusitis (mucosa thickens) gives the embodiment of the invention 3 Flos Lonicerae balls 9 grams; Every day 2 times, oral and period in a medicine was withdrawn " tablet for alleviating pain ", and not recurrence in 1 year is followed up a case by regular visits in the back recovery from illness of 2 weeks.
Claims (4)
1. a Chinese medicine composition of treating chronic sinusitis is characterized in that being processed by each crude drug of following portions by weight: 25 ~ 35 parts of Flos Loniceraes, 15 ~ 25 parts of Flos Magnoliaes, 10 ~ 20 parts of Fructus Xanthii, 10 ~ 20 parts of the Radixs Angelicae Dahuricae, 7 ~ 17 parts of Radix Scutellariaes, 10 ~ 20 parts of Radix Bupleuri, 10 ~ 20 parts of Radix Gentianaes, 7 ~ 17 parts of the Rhizoma Anemarrhenaes, 15 ~ 25 parts of the Radixs Astragali, 5 ~ 15 parts of Herba Asaris, 5 ~ 15 parts in Radix Glycyrrhizae.
2. the Chinese medicine composition of treatment chronic sinusitis as claimed in claim 1 is characterized in that being processed by each crude drug of following portions by weight: 30 parts of Flos Loniceraes, 20 parts of Flos Magnoliaes, 15 parts of Fructus Xanthii, 15 parts of the Radixs Angelicae Dahuricae, 12 parts of Radix Scutellariaes, 15 parts of Radix Bupleuri, 15 parts of Radix Gentianaes, 12 parts of the Rhizoma Anemarrhenaes, 20 parts of the Radixs Astragali, 10 parts of Herba Asaris, 10 parts in Radix Glycyrrhizae.
3. according to claim 1 or claim 2 the Chinese medicine composition of treatment chronic sinusitis is characterized in that: process any acceptable clinically preparation by conventional method.
4. the Chinese medicine composition of treatment chronic sinusitis as claimed in claim 3 is characterized in that: said preparation is the watered pill or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110309935 CN102327451B (en) | 2011-10-13 | 2011-10-13 | Chinese medicinal composition for treating chronic sinusitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110309935 CN102327451B (en) | 2011-10-13 | 2011-10-13 | Chinese medicinal composition for treating chronic sinusitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102327451A true CN102327451A (en) | 2012-01-25 |
| CN102327451B CN102327451B (en) | 2013-04-03 |
Family
ID=45479582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110309935 Expired - Fee Related CN102327451B (en) | 2011-10-13 | 2011-10-13 | Chinese medicinal composition for treating chronic sinusitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102327451B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127570A (en) * | 2014-06-18 | 2014-11-05 | 陈筠 | Traditional Chinese medicine composition for treating chronic rhinitis |
| CN109512960A (en) * | 2019-01-09 | 2019-03-26 | 郝杰兵 | A kind of pharmaceutical formulation for treating rhinitis and nasosinusitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491615A (en) * | 2009-02-25 | 2009-07-29 | 韩伯杨 | Medicine for treating rhinitis and its preparation method |
-
2011
- 2011-10-13 CN CN 201110309935 patent/CN102327451B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491615A (en) * | 2009-02-25 | 2009-07-29 | 韩伯杨 | Medicine for treating rhinitis and its preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 丁学敏等: "鼻炎丸治疗慢性鼻炎264例效果观察", 《中国医药导报》 * |
| 郝铁来等: "清鼻汤治疗慢性鼻炎、鼻窦炎", 《河南中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127570A (en) * | 2014-06-18 | 2014-11-05 | 陈筠 | Traditional Chinese medicine composition for treating chronic rhinitis |
| CN109512960A (en) * | 2019-01-09 | 2019-03-26 | 郝杰兵 | A kind of pharmaceutical formulation for treating rhinitis and nasosinusitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102327451B (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103301400A (en) | Traditional Chinese medicinal composition for treating chronic atrophic gastritis and preparation method of traditional Chinese medicinal composition | |
| CN103191382B (en) | Medicine for treating Bi syndrome and preparation method thereof | |
| CN102512552B (en) | Traditional Chinese medicine composition for treating exogenous fever | |
| CN102327451B (en) | Chinese medicinal composition for treating chronic sinusitis | |
| CN104306793A (en) | Chinese herba preparation for treating lobar pneumonia | |
| CN101579185B (en) | Pharmaceutical rhinitis pillow for external use and treating wind-cold rhinitis | |
| CN103830481B (en) | The medicine for the treatment of infantile respiratory tract infection repeatedly | |
| CN102895371B (en) | Traditional Chinese medicine for treating diarrhea type irritable bowel syndrome | |
| CN104873911A (en) | Traditional Chinese medicine for oral administration for adjunctively treating sepsis | |
| CN104800742A (en) | Chinese medicinal composition for treating rhinitis and preparation method thereof | |
| CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
| CN104013836A (en) | Traditional Chinese medicine composition for treating sequela of cerebral apoplexy | |
| CN102895533A (en) | Traditional Chinese medical preparation for treatment of cervical vertigo | |
| CN102166319B (en) | Soup for treating wind cold | |
| CN101953999B (en) | Medicinal composition for treating paralysis and preparation method thereof | |
| CN101502597A (en) | Medicament for treating stomachache and preparation method thereof | |
| CN105362596A (en) | Traditional Chinese medicine for treating pulmonary emphysema and preparation method thereof | |
| CN104474173A (en) | Medicine for treating facial nerve paralysis | |
| CN105288511A (en) | Traditional Chinese medicine composition for treating scapulohumeral periarthritis and preparation method thereof | |
| CN104758346A (en) | Medicine for treating migraine, as well as preparation method and preparation of medicine | |
| CN1296091C (en) | Chinese traditional medicine composition for treating psoriasis | |
| CN104027571A (en) | Traditional Chinese medicine composition for treating chronic pulmonary heart disease | |
| CN104225281A (en) | Traditional Chinese medicine for treating nasosinusitis | |
| CN102114183A (en) | Medicament for treating hypertension | |
| CN104189315B (en) | A kind of Chinese medicine for the treatment of expectorant blood stasis type globus hystericus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130403 Termination date: 20141013 |
|
| EXPY | Termination of patent right or utility model |